| An Australian biotechnology firm is seeking approval in the U.S. to sell a relatively new medical product for Fidos. The company, Queensland-based Plasvacc, manufactures Caniplas - a plasma product for dogs that is produced by removing blood cells from canine blood. It is used in treating dogs for infections, poisoning and diarrhea.
According to the firm, Plasvacc’s technology is similar to that used in human blood banks, "with many proprietary improvements and changes, as well as proprietary regimes in hyperimmunization, quality control, donor selection, and donor husbandry."
Plasvacc has been producing horse and camel plasma for several years. Canine plasma is a new product. The company tells the Courier Mail that veterinarians will need to be educated about the uses for Caniplas plasma, but the expectation is that US sales will reach 20-million dollars over the next five years if regulatory approval to sell in the States is granted.
|
